Metabolism Disorder TRIZ Cases

Higher weekly semaglutide dosing targets obesity-linked HFpEF to improve symptoms, physical function, and hospitalization risk.

Non-naturally occurring melanocortin antagonist analogs use sequence and cyclization changes to improve appetite stimulation and body weight gain.

Specific PP amino acid substitutions target NPY4R to combine weight loss and glucose control while avoiding GI side effects.

Formulations of GIP/GLP-1 dual agonists use minimal non-aqueous solvents to cut GI side effects while supporting higher dosing and compliance.

ROCK inhibitor with KGF and/or EGF expands pancreatic endoderm cells while preserving differentiation potential for regenerative medicine.

Every-other-day migalastat dosing helps Fabry patients with renal impairment stabilize kidney function and increase α-Gal A activity.

Oral migalastat stabilizes amenable α-Gal A variants, lowering podocyte GL-3 and left ventricular mass in Fabry disease.

Fatty acid-linked insulin derivatives extend duration of action and bioavailability, helping reduce injection frequency while maintaining efficacy.

An initial burst inhibiting agent in biodegradable tirzepatide microspheres extends drug release while reducing injection-site pain and inflammation.

Fatty acid side-chain modification helps polypeptide drugs achieve oral absorption while preserving activity, selectivity, and stability.

Every-other-day migalastat boosts α-Gal A activity to lower left ventricular mass and podocyte GL-3 burden in Fabry disease.

Migalastat stabilizes mutant α-Gal A in Fabry disease, improving enzyme trafficking and reducing substrate buildup in key tissues.

Separate SNAC and GLP-1 granules enable simultaneous release in the gut, improving predictable oral peptide bioavailability.

Extended-release bexagliflozin tablets use gastric retention and granule-based release to lower Cmax while maintaining therapeutic levels.

Gradual weekly dose escalation of a long-acting GGG incretin analog improves glycemic control and weight management while limiting GI adverse events.

An rAAV vector co-expresses NEU1 and PPCA to treat sialidosis while avoiding the severe immune response seen with enzyme replacement.

Selective ACC2 inhibition treats fatty liver while avoiding the triglyceride rise and platelet loss seen with ACC1/2 dual inhibitors.

Gradual weekly escalation of a long-acting GGG incretin analog improves glycemic control and weight management while limiting GI adverse events.

Combining a THRβ agonist with a GLP-1R agonist improves weight loss and fat reduction at lower GLP-1R doses with fewer GI side effects.

Patient-specific ADM ranking and dosing combine guidelines with real-time data to improve glycemic control while reducing treatment complexity.

By removing hygroscopic and incompatible excipients, this linagliptin tablet formulation improves stability, dissolution, and bioavailability.

Dental pulp stem cell supernatant with microparticles suppresses IL-6 and TNF-α to improve weight loss, anemia, and undernutrition.

Oral SLC6A19 inhibitor dosing lowers systemic phenylalanine in PKU by limiting renal reabsorption, offering an alternative to diet and enzyme therapy.

PEGylation and zinc complexation extend insulin half-life and action duration, supporting once-weekly dosing with steadier glucose control.

Adding obicetrapib to high-intensity statins helps hypo-responders lower LDL-C, ApoB, and non-HDL-C to reduce ASCVD risk.

A tuned EPA:MA ratio with leucine boosts muscle protein synthesis and helps maintain muscle mass in subjects facing muscle decline.

A redox motif linked to the LALEGSLQK epitope boosts IFN-gamma, Granzyme B, and cytolytic CD4+ T cell generation for type 1 diabetes.

Avian IgY antibodies block the extracellular glucose-binding domain of SGLT1 to lower blood glucose without hypoglycemia or GI side effects.

Chicken immunization overcomes low-density, unstable GIPR targets to produce inhibitory antibodies with broad mammalian cross-reactivity.

Spatial covariance modeling predicts phenotype landscapes from gene variants, helping match patients to drug treatments with better response accuracy.

A waffle-like planar hydrogel macrodevice spaces encapsulated islet microtissues to shorten diffusion paths and support vascularization.

Serum-free glycoprotein production raises sialic acid and M6P levels, improving serum half-life, uptake, and immunogenicity.

A peptide antagonist blocks α9β1 integrin on adipose macrophages to curb inflammation and improve insulin sensitivity in obesity disorders.

Co-transplanting islet cells with parathyroid-derived or CD34+ cells improves vascularization and graft survival in accessible extrahepatic sites.

Targeted MetAP2 conjugates use cleavable linkers to improve obesity treatment while reducing systemic toxicity and side effects.

A two-layer dapagliflozin-metformin tablet balances rapid onset and 24-hour glucose control by separating immediate and extended release.

Screened soybean hydrolysate peptides inhibit cholesterol esterase to lower serum cholesterol and triglycerides without statin-linked diabetes risk.

Encapsulating mitochondria in induced microvesicles enables scalable production, longer preservation, and easier transfer into damaged cells.

Polyglycerol esters of 3-oxobutyric acid enable stable ketone release with better tolerance, longer plasma action, and scalable production.

Small-molecule PCSK9 antagonists address the oral delivery gap by combining strong LDL-lowering activity with favorable pharmacokinetics.

Fatty-acid acylation and hydrophilic linkers extend insulin half-life while improving stability, bioavailability, and injection frequency.

Micronized lutein and zeaxanthin with solubility enhancers and antioxidants improve GI absorption while limiting oxidation.

Specific neuraminidase mutations with cathepsin A prevent intracellular crystallization and improve lysosomal localization for gene therapy.

Retro-Michael resistant albumin-linker coupling keeps GLP-1/GIP/glucagon agonists stable, long-acting, and less prone to adverse effects.

Reversible albumin binding extends peptide and protein drug half-life, reducing renal clearance and injection frequency.

Antibodies bind extracellular insulin receptor regions to tune insulin affinity, improving glucose uptake and lowering blood glucose with fewer side effects.

Fixed ActRII antibody doses replace weight-based calculations, enabling subcutaneous self-administration with optimized PK/PD and fewer dosing errors.

Histidine, methionine, polysorbate, and sorbitol or mannitol stabilize anti-INSR antibody formulations and preserve potency during storage.

Combining a SARM with GLP-1 or SGLT-2 weight loss drugs helps preserve lean mass, maintain strength, and limit rebound weight gain.